{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.4","upperLimit":"82.4","value":"74.5"},{"groupId":"OG001","lowerLimit":"8.5","upperLimit":"22.5","value":"14.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"Overall response rate was defined as the percentage of participants who achieved a best overall response of complete response or partial response.\n\nComplete response was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \\& biopsy.\n\nPartial response was defined as \\>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \\> 100000/μL platelets, \\> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors.","dispersionType":"95% Confidence Interval","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"OG000","title":"Idelalisib + Rituximab"},{"description":"Placebo to match idelalisib administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"OG001","title":"Placebo + Rituximab"}],"paramType":"NUMBER","populationDescription":"ITT Analysis Set: randomized participants with treatment group designated according to initial randomization.","reportingStatus":"POSTED","timeFrame":"Up to 17 months","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}